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PROBLEM
The inherent need for medication transitions for patients with
pulmonary arterial hypertension (PAH) and paucity of available
primary literature drives the impetus for development and
evaluation of proprietary transition protocols.

BACKGROUND

126 patients
transitioned
between
1/1/2016 to
12/31/2019

48 patients did
not meet
inclusion
criteria:
Transition not
meeting patient
criteria

5 met exclusion
criteria:
3 transitioned with
intent for hospice
facilitation
2 stopped
medication during
transition
admission

IV epoprostenol to IV treprostinil – 20 (27.4%)

Medication transitions are done to:
• Minimize adverse drug reactions
• Optimize disease management
• Change route of administration
• Improve quality of life by facilitating ease of therapy

Inhaled treprostinil to parenteral treprostinil – 8 (11%)

OBJECTIVE
To assess the efficacy and safety of current PAH medication
transition practices and protocols at our institution.

METHODS
• Retrospective, observational, single-center study of PAH
patients at St. Luke’s Medical Center in Milwaukee, WI
• Included adult PAH patients transitioned between PAH
medications from January 2016 through December 2019
• Patients identified via pulmonary hypertension clinic records
• All patients transitioned based on institutional protocol
references.
• Protocols included transitioned at least six patients
• Data collected included baseline demographics, baseline and
post-transition hemodynamics, acute transition safety and
efficacy, and six-month safety.
• Composite primary efficacy outcome: transition success,
defined as transition to new medication without worsening
of disease, new intolerable side effects at first follow-up,
increased escalation of care or death within 1 month.
• Primary safety outcome was escalation of care

N=73
patients
included

Figure 2. Transition Breakdown

A wide variety medications are available for the treatment of
PAH. Due to nuances between medications even within a
certain medication class, there is the need for medication
transitions when managing these patients.

Transitioning between medications comes with risks such as
prostacyclin excess, insufficiency, and patient decompensation.

Table 3. Periprocedural Hemodynamics

Table 1 continued. Baseline Demographics

Figure 1. Patient Flow Diagram

Parenteral treprostinil to oral treprostinil – 15 (20.5%)

PH Markers (n=73)
Number (%)
6 Minute Walk Distance (6MWD) (m)
Pre (n=51) Pre (n=38)

Primary Reason for transition
Side Effect 22 (30.1%)
Ease of therapy 19 (26%)
Planned procedure 12 (16.4%)
Worsening PAH 12 (16.4%)
Line complications 7 (9.6%)
Insurance 1 (1.4%)
Location of transition
Hospital Admission 38 (52.1%)
Outpatient Observation Unit 19 (26%)
At home 10 (13.7%)
Hospital Admission ICU 6 (8.2%)

Baseline 6MWD and repeat 6MWD
390
post transition (m)
(45-658)
Patients 6MWD above or with <30m
--decrease in 6MWD
ECHO Parameters
Pre (n=73)

Oral treprostinil to parenteral treprostinil – 11 (15.1%)

SubQ treprostinil to IV treprostinil – 7 (9.6%)
IV treprostinil to SubQ treprostinil – 6 (8.2%)
Parenteral treprostinil to inhaled treprostinil – 6 (8.2%)

Table 1. Baseline Demographics
Demographics (n=73)
Number (%)
Female
49 (67.1%)
Age (years), median (range)
62 (21-89)
Weight (kg), median (range)
89 (40-140)
BMI (kg/m2), median (range)
31.59 (15.48-56.79)
Patients with baseline oxygen use
52 (71.2%)
PH diagnosis (WHO)
Group 1 64 (87.7%)
Group 1 and Group 4 5 (6.8%)
Group 1 and Group 2 2 (2.7%)
Group 1 and Group 3 1 (1.4%)
Group 1, Group 3 and Group 4 1 (1.4%)
Concomitant PAH medications
No concomitant medications 21 (28.8%)
Prostacyclin + Nitric Oxide Pathway 36 (49.3%)
(tadalafil, sildenafil, riociguat)
Prostacyclin + Endothelin Receptor 5 (6.8%)
Antagonist
(ambrisentan, bosentan, macitentan)
Triple therapy 11 (15.1%)
Baseline Functional Class
Functional Class 1 3 (4.1%)
Functional Class 2 20 (27.4%)
Functional Class 3 35 (47.9%)
Functional Class 4 15 (20.5%)

RESULTS
•
•
•
•

73 patients comprised the final cohort
7 unique transition protocols evaluated
69 successful transitions (94.5%) and 4 complications
67 patients (91.8%) acutely achieved planned target dose

•
•
•
•

Four complications occurred including:
2 requiring escalation of care
1 intolerable side effect requiring discontinuation
1 death during the transition admission unrelated to
medication transition

Baseline and repeat PASP (mmHg),
62
median
(28-133)
Baseline and repeat TAPSE (mmHg),
20
median
(10-33)
Repeat PASP below baseline or <10%
--increase from baseline
Repeat TAPSE above baseline or <10%
--decrease from baseline (n=66)
RHC Parameters
Pre (n=63)

Post (n=38)

417
441
(150-658)
(152-639)
28 (73.7%)

Pre (n=69)

Post (n=69)

61
63
(28-133)
(31-133)
21
20
(10-33)
(6-38)
38 (55.1%)
48 (72.7%)

Pre (n=13)

Post (n=13)

Baseline and repeat mPAP (mmHg),
47
44
38
median
(21.7-67)
(25-60)
(23-65)
Baseline and repeat PVR (wood units),
7.22
5.7
4.3
median
(1.5-22.92) (1.5-14.7) (1.3-17.5)
Baseline and repeat CI by thermo
2.61
2.56
3.12
(L/min/m2), median
(1.01-6.11) (1.01-6.11) (2.24-4.91)
Baseline and repeat CI by Fick
2.18
2.19
2.67
2
(L/min/m ), median
(1.06-3.5) (1.44-3.5) (1.07-3.7)

INDIVIDUAL
TRANSITION DATA

• 21 patients (28.8%) experienced prostacyclin excess
• 7 patients (9.6%) experienced prostacyclin insufficiency
Table 2. Results
Acute Transition (n=73)
Number (%)
Success
69 (94.5%)
Reason for transition complication
Transitioned to new medication 73 (100%)
Without worsening of disease 72 (98.6%)
Without intolerable side effect requiring 72 (98.6%)
discontinuation
Without escalation of care 71 (97.3%)
Without death in 1 month 72 (98.6%)
Target dose achieved acutely
67 (91.8%)
Prostacyclin excess during transition
21 (28.8%)
Prostacyclin insufficiency during transition
Dosing protocol adjustment required
Dosing protocol adjustment required
Functional class maintained at first follow-up visit
Long Term Outcomes
Death in 1 month
Lung transplant or balloon septostomy in 6 months

7 (9.6%)
15 (20.5%)
15 (20.5%)
70 (95.9%)
Number (%)
1 (1.4%)
0 (0%)

CONCLUSIONS
Transitions of PAH medications appears safe and efficacious
when following our institutional guideline protocols
Patients may require acute adjustments to transition protocol
based on side effects, prostacyclin insufficiency, and patient
reason for transition (20.5%).
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